Welcome to the official InxMed website
About Us

About Us

>
History
All categories
2018

Company founded Tens of millions USD of A round raised Preliminary R&D pipeline established

Jan,2019

Opening of InxMed Shanghai & Beijing offices

Sep, 2019

IN10018 Received US FDA IND Approval

Oct, 2019

Achieved clinical collaboration with Roche for IN10018 co-development

Dec, 2019

IN10018 Phase I Clinical Trial in China approved

Jan,2020

Achieved clinical collaboration with Merck for IN10018 co-development

Mar,2020

First patient enrolled in the US

Apr,2020

Investigational New Drug (IND) application approved for IN10018 combined with chemotherapy for the treatment of high-grade serous ovarian cancer 

Jul,2020

First patient enrolled in China

Sep,2020

Closed 130 million RMB of A+ round

Feb,2021

Opening of InxMed R&D and Translational Research Center

Aug,2021

IN10018 Received US FDA Fast Track Designation

Sep,2021

Published the result of IN10018 synergized with KRAS G12C Inhibitors to improve treatment outcomes for KRAS G12C mutant cancers

Mar, 2022

Closed US $50M Series B Financing

Apr, 2022

IN10018 Received NMPA Breakthrough Designation

May, 2022

Closed US $15M Series B+ Financing

Jun,2022

Announced that result of an open-label phase Ib trial of IN10018 in PROC in ASCO 2022

Sep,2022

Announced first patient dosed in pivotal phase 2 study of IN10018 in PROC

Oct,2022

Released data demonstrating IN10018 therapeutic potential in metastatic melanoma at SMR 2022

Aug,2023 

Received approval to initiate phase I clinical trial in China for OMTX705

Oct,2023

Released data at 14th Annual World ADC highlighting synergy of IN10018 with ADCs and novel stroma targeting pipeline

Oct,2023

Released data demonstrating IN10018 trending toward survival benefit for PROC and TNBC at ESMO 2023

Dec,2023

Entered license agreement with Escugen to develop next-generation ADCs

 InxMed

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO